ATE380875T1 - Chimäre proteine zur vermeidung der komplementaktivierung - Google Patents

Chimäre proteine zur vermeidung der komplementaktivierung

Info

Publication number
ATE380875T1
ATE380875T1 AT94931763T AT94931763T ATE380875T1 AT E380875 T1 ATE380875 T1 AT E380875T1 AT 94931763 T AT94931763 T AT 94931763T AT 94931763 T AT94931763 T AT 94931763T AT E380875 T1 ATE380875 T1 AT E380875T1
Authority
AT
Austria
Prior art keywords
chimeric proteins
complement activation
avoid complement
avoid
polypeptide
Prior art date
Application number
AT94931763T
Other languages
English (en)
Inventor
Jone-Long Ko
Paul J Higgins
C Grace Yeh
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE380875T1 publication Critical patent/ATE380875T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94931763T 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung ATE380875T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12659693A 1993-09-24 1993-09-24
US08/310,416 US5679546A (en) 1993-09-24 1994-09-22 Chimeric proteins which block complement activation

Publications (1)

Publication Number Publication Date
ATE380875T1 true ATE380875T1 (de) 2007-12-15

Family

ID=26824842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931763T ATE380875T1 (de) 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung

Country Status (9)

Country Link
US (2) US5679546A (de)
EP (1) EP0723555B1 (de)
JP (2) JP3860605B2 (de)
CN (1) CN1057097C (de)
AT (1) ATE380875T1 (de)
AU (1) AU697167B2 (de)
CA (1) CA2172610A1 (de)
DE (1) DE69435049D1 (de)
WO (1) WO1995008570A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
WO1999022759A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
JP4437192B2 (ja) * 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
AU2400500A (en) * 1999-11-01 2001-05-14 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
EP2113516B1 (de) 2000-10-10 2014-05-21 Genentech, Inc. C5 Antikörper, die die Typ II Aktivierung von Endothelialzellen inhibieren
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
NZ529044A (en) * 2001-06-08 2008-03-28 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
CA2499075A1 (en) * 2002-09-16 2004-03-25 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
US8124097B2 (en) * 2004-01-21 2012-02-28 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
EP1742651B1 (de) * 2004-03-31 2011-03-09 The Feinstein Institute for Medical Research Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
US8911733B2 (en) * 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
PT2500030E (pt) * 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
PL2907827T3 (pl) * 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
NZ578873A (en) * 2007-03-01 2012-01-12 Wellstat Ophthalmics Corp Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
EP2496259B1 (de) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Behandlung von paroxysmaler nächtlicher hämoglobinurie
CN102234332B (zh) * 2010-04-26 2014-12-17 浙江海正药业股份有限公司 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
EP2723361B1 (de) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Verfahren zur behandlung chronischer erkrankungen mit komplementinhibitoren
JP6244350B2 (ja) 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160126054A (ko) 2014-02-27 2016-11-01 알러간, 인코포레이티드 보체 인자 Bb 항체
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
RU2698205C2 (ru) 2014-12-18 2019-08-23 Ф. Хоффманн-Ля Рош Аг Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
EP3359663A4 (de) 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania Zusammensetzung und verfahren zur behandlung einer komplementvermittelten erkrankung
EP3368074A2 (de) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-faktor-d-antikörper und -konjugate
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
AU2016375183B2 (en) * 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation
KR102566634B1 (ko) 2016-06-28 2023-08-14 우니베르시테트 울름 보체 억제제 및 그의 용도
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
KR20210151918A (ko) * 2019-04-13 2021-12-14 내쇼날 센터 포 셀 사이언시즈 Daf-mcp 키메라 단백질, 이의 제조 방법 및 보체계 관련 병리학적 상태 치료를 위한 상기 키메라 단백질의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
JP3115318B2 (ja) * 1989-08-22 2000-12-04 イミュネックス・コーポレーション Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
JPH04506460A (ja) * 1990-01-26 1992-11-12 バイオジェン，インコーポレイテッド Ｃ４結合タンパク質の融合タンパク質
EP1413587A2 (de) * 1991-05-03 2004-04-28 Washington University Modifizierter Regulator des Komplementsystems
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
US5679546A (en) 1997-10-21
AU8071994A (en) 1995-04-10
AU697167B2 (en) 1998-10-01
DE69435049D1 (de) 2008-01-24
CN1057097C (zh) 2000-10-04
JPH09502985A (ja) 1997-03-25
CN1138863A (zh) 1996-12-25
EP0723555B1 (de) 2007-12-12
US5851528A (en) 1998-12-22
EP0723555A1 (de) 1996-07-31
EP0723555A4 (de) 1999-04-28
CA2172610A1 (en) 1995-03-30
WO1995008570A1 (en) 1995-03-30
JP2005041882A (ja) 2005-02-17
JP3860605B2 (ja) 2006-12-20

Similar Documents

Publication Publication Date Title
DE69435049D1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
NO965362L (no) Syntetiske lederpeptidsekvenser
NO971875L (no) Cathepsin 02 protease
TW430669B (en) A hybrid toxin fragment and their use
ATE189475T1 (de) Wachstums-differenzierungsfaktor der tgf-b familie
ATE226634T1 (de) Fibronektin bindendes protein
ATE328101T1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE389023T1 (de) Kontrolle der schotendehiszenz
EP0422125A4 (en) Platelet blocking peptides
NO971059L (no) Modifiserte human-C3-proteiner
ES2058479T3 (es) Compuestos peptidicos.
ATE285474T1 (de) Haemophilus adhäsionsproteinen
PT635025E (pt) Processo para preparar proteinas modificadas
AU669149B2 (en) Expression signal-peptide-free staphylokinases
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
DE3881123D1 (de) Klonieren von fuer einen antibakteriellen polypeptidvorlaeufer kodierender dna und expression des vorlaeufers.
DK0826054T3 (da) Ekspression af glycosyltransferase i Aspergillus
FI884112A7 (fi) Aspergillus Nidulans isopenisilliini-N-syntetaasia koodaavat rekombinantti-DNA -ilmaisuvektorit ja DNA-sekvenssit.
EP0714982A3 (de) Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
ES2012283A6 (es) Procedimiento de obtencion de una proteina de endotoxina de efecto insecticida.
ATE193324T1 (de) Rekombinante herstellung von laktoperoxidase
ATE231887T1 (de) Protein mit anti-tumorwirkung
FI881870A7 (fi) L-fenyylialaniinin valmistus rekombinanttibakteerien avulla.
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties